Evidence map›Paper›PMID 41035181›Full record

ReviewInternal medicine journal2025

HIV: is it now a thing of the past?

Jeffrey John Post

Abstract readReview
In one paragraph

Review in Internal medicine journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Jeffrey John PostDepartment of Infectious Diseases, Prince of Wales Hospital, Sydney, New South Wales, Australia.ORCID 0000-0003-1475-9272

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Effective antiviral therapy for human immunodeficiency virus (HIV) has substantially reduced HIV-associated morbidity and mortality for people living with HIV (PLWH). The use of antiviral therapies as prevention, most notably pre-exposure prophylaxis (PrEP) as well as treatment as prevention (TasP), has significantly reduced the number of new infections in those using these biomedical prevention approaches (PrEP) and their sexual partners (TasP). However, nearly one-quarter of new HIV infections globally occur in the Asia-Pacific region (approximately 300 000 per annum) with a substantial number of deaths annually. Despite therapeutic advances, the total number of PLWH has increased worldwide. Although antiviral therapy has substantially reduced HIV-specific morbidity and mortality and is associated with significantly increased longevity, PLWH experience higher rates of chronic comorbidities than the general population. It is important that preventative approaches such as immunisation against specific conditions, lifestyle modification, smoking cessation and cancer screening are optimised for PLWH. Physicians are likely to care for PLWH in almost all subspecialties including aged care. Recent data support the use of organ transplantation in PLWH including from donors who also have HIV infection. HIV is most certainly not 'a thing of the past'.

Indexed as

Anti-HIV AgentsHIV InfectionsPre-Exposure ProphylaxisHumansAnti-HIV Agentsantiretroviral treatmentcomorbiditieshuman immunodeficiency viruspreventiontransplantation

Identifiers

PMID41035181
PMCPMC12704400

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.